Skip to main content
Figure 2 | Cardiovascular Diabetology

Figure 2

From: The sodium glucose cotransporter 2 inhibitor empagliflozin does not prolong QT interval in a thorough QT (TQT) study

Figure 2

Placebo-corrected QTcN CfB (A) and placebo-corrected heart rate CfB (B). Data are adjusted means and 90% confidence intervals (CIs) after administration of empagliflozin 25 mg, or 200 mg, or moxifloxacin 400 mg. Data from the full analysis set analysed: placebo (n=29); 25 mg empagliflozin group (n=28); 200 mg empagliflozin group (n=30); and 400 mg moxifloxacin group (n=29). CfB, change from baseline; HR, heart rate; QTcN, population heart rate-corrected QT interval.

Back to article page

Cardiovascular Diabetology

ISSN: 1475-2840